{"entity":{"id":"azd5492","kind":"drug","name":"AZD5492","aka":[],"tldr":"AZD5492 is an experimental T-cell engager from AstraZeneca in phase 2 trials, aimed at CD20.","summary":"AZD5492 is a T-cell engager developed by AstraZeneca. Its target is CD20 (the sponsor names CD20). The sponsor states: A CD8/TCR-based T-cell engaging antibody targeting CD20, administered subcutaneously to redirect T cells against CD20-positive B-cell malignancies. ClinicalTrials.gov describes the intervention as: CD8/TCR based T-cell engaging antibody targeting CD20, which is administered subcutaneously. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06542250, plans to enrol 174 participants with primary completion expected 2029-12-18. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of AZD5492","url":"https://clinicaltrials.gov/search?intr=AZD5492"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["cd20"],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06542250"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"T-cell engager","mechanism":"A CD8/TCR-based T-cell engaging antibody targeting CD20, administered subcutaneously to redirect T cells against CD20-positive B-cell malignancies.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/azd5492/","neighbours":{"target":[{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"trial":[{"id":"nct06542250","kind":"trial","name":"A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.","route":"/trials/nct06542250/"}]}}